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Abstract: The treatment of diseases that affect the central nervous system (CNS) represents a great
research challenge due to the restriction imposed by the blood–brain barrier (BBB) to allow the passage
of drugs into the brain. However, the use of modified nanomedicines engineered with different
ligands that can be recognized by receptors expressed in the BBB offers a favorable alternative for
this purpose. In this work, a BBB-penetrating peptide, angiopep-2 (Ang–2), was conjugated to
poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles through pre- and post-formulation strategies.
Then, their ability to cross the BBB was qualitatively assessed on an animal model. Proof-of-concept
studies with fluorescent and confocal microscopy studies highlighted that the brain-targeted PLGA
nanoparticles were able to cross the BBB and accumulated in neuronal cells, thus showing a promising
brain drug delivery system.
Keywords: PLGA; PEG; PF127; angiopep-2; nanoparticles; blood–brain barrier
1. Introduction
Discovering new methods to treat diseases is becoming increasingly complicated because of the
numerous natural biological barriers in our bodies such as opsonization by proteins in the blood,
first-pass clearance organs, and the immune response [1,2]. The difficulty of overcoming these barriers
to create a cure is exponentially increased when trying to deliver pharmaceutics across the blood–brain
barrier (BBB) [3,4]. This is due to the brains increased security including tight junctions, low molecule
diffusion rates, efflux transporters, and difficulty in reaching sufficient drug exposure in the brain
compartment [5]. Nanomedicine has been the leading field in surpassing these barriers to deliver drugs
to the brain. This is because their physico-chemical characteristics can be controlled to improve drug
solubility, compatibility in BBB interactions, and can be targeted using ligands specific to improve
delivery into the brain [6–8].
A very promising targeting ligand for the delivery of nanomedicines into the brain is Angiopep-2
(Ang–2), a 19 amino acid peptide (TFFYGGSRGKRNNFKTEEY-OH) which binds the low-density
lipoprotein receptor-related protein 1 (LRP1), which is widely expressed throughout the central nervous
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system (CNS) (by endothelial cells on the basolateral surface, neuroblasts, microglia, astrocytes, and
neurons) [9–12]. This ligand has been highly sought after in its use to deliver nanomedicines to the
brain because of its ability to activate transcytosis across the BBB, as well as its upregulation in human
glioma cells [13–15]. To this end, Ang–2 has been conjugated to numerous nanocarrier types in order
to improve BBB crossing, including liposomes, tandem micelles, PEG-PCL, solid lipid nanoparticles,
dendrigraft poly-l lysine, and poly-amidoamine dendrimers to deliver various active compounds
(Coumarin, docetaxel, siRNA, etc.) [16–19].
Poly(lactic-co-glycolic acid) (PLGA) is an FDA approved polymer that can self-assemble into
nanoparticles, with selectable features including the size, shape, charge, and drug loading capacity
as a function of the formulation parameters. Moreover, literature extensively reported its ability to
encapsulate, protect, and deliver a wide range of bioactive compounds (small molecules, proteins,
enzymes, etc.) [20–22]. However, only a few studies indicated that PLGA-based nanoparticles modified
with Ang–2 could be a promising active brain-targeting drug delivery system [13,14,18,23,24]. In this
work, we focused on creating and characterizing targeted Ang–2 PLGA nanoparticles (NPs); the surface
was engineered by conjugating Ang–2 directly to the polymer, and nanoformulation was then gained,
or with post-formulation anchorage to NP through the conjugation of the thiol-containing cysteine
added to the Ang–2 and a maleimide containing PLGA. These NPs were then characterized for their
amount of Ang–2 bound to the NPs and tested in vivo for their ability to pass the BBB and enter into
the brain parenchyma. Moreover, technological and methodological procedures to produce engineered
nanomedicines proposed in our work are quite simple and easy to be adapted from brain delivery of
other potential drugs, therefore spreading the possibility of application in other brain diseases.
2. Materials and Methods
2.1. Materials
Poly(lactic-co-glycolic acid) of molecular weight 24–38 kDa (PLGA 50:50) and Pluronic F127®
were purchased from Sigma-Aldrich (Milan, Italy). The PLGA-b-PEG copolymer was previously
obtained through the modification of PLGA with mPEG-NH2 (MW: 5000 Da) [22]. The PLGA
(Resomer 503 H) derivatized with the fluorophore Cy5 was obtained by the Laboratory of
Nanomedicine and Pharmaceutical Technology of the University of Modena and Reggio Emilia
(Modena, Italy) as previously reported [25]. The PLGA-Mal (MW: 20 kDa) was purchased from
Nanosoft Biotechnology (Lewisville, TX, USA). The modified Angiopeptide-2 with a cysteine end
group (CTFFYGGSRGKRNNFKTEEY), referred to from now as Ang–2, was synthesized by the
company GenScript (MerckMillipore, Oregon City, OR, USA). The ultrapure water was supplied by
a Milli-Q® water purification system (Synergy® UV, Darmstadt, Germany). All the solvents and
other reactive products were also of a high degree of purity (>95%) and used as purchased without
modification, unless otherwise stated.
2.2. Animals
For the in vivo tests, C57BL/6 mice were used. The experiments were carried out in accordance with
the European Communities Council Directives of 24 November 1986 (86/609/EEC) for experimental care.
2.3. Synthesis and Characterization of PLGA Conjugate with the Ang–2
The conjugation between Ang–2 and PLGA was carried out by reacting the maleimide group,
present on the glycolic acid terminus of the PLGA chains, with the cysteine thiol group originating
from the peptide, as shown in Figure 1 [4,26]. Briefly, 20 mg of PLGA-Mal together with 1.2 mg of
the peptide (molar ratio PLGA-Mal/Ang–2 2:1) were dissolved in 4 mL anhydrous dimethyl sulfoxide
(DMSO). After 15 h of reaction under constant agitation, the modified polymer was precipitated
by adding diethyl ether [27]. Finally, the polymer was dried under reduced pressure and stored for
characterization and use in the preparation of nanoparticles [28].
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Figure 1. Scheme of PLGA functionalization with Ang–2.
Modified PLGA products (PLGA-Ang–2) were analy ed by 1H-NMR to confirm the presence
of Ang–2. The conjugate and control samples (3 mg) were dissolved in deuterated DMSO (0.5 µL),
and the spectrum was obtained in a Bruker 400 MHz spectrometer.
2.4. Pre aration of PLGA Nanoparticles Functionalized with Ang–2 (Ang–2-NPs)
For comparative purposes, the polymer nanoparticles were obtained through the nanoprecipitation
method using two different conjugation strategies: pre and post-functionalization (Figure 2) [29].Pharmaceutics 2019, 11, x FOR PEER REVIEW 4 of 12 
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Figure 2. Schematic representation of the modification of PLGA/PLGA-b-PEG nanoparticles with
Ang–2 through (A) pre-functionalization and (B) post-functionalization.
The pre-formulation functionalized nanoparticles (pre-formulation Ang–2 NPs) were prepared
from mixtures with the following composition: PLGA (42.5%), PLGA-b-PEG (42.5%), PLGA-Cy5 (5%),
and PLGA-Ang–2 (10%, synthesized as described above). An exact amount (10 mg) of the mixture
was dissolved in 2 mL of acetone and subsequently added dropwise to 4 mL of a PF127 solution
(1.0% w/v). Finally, the organic solvent was removed under reduced pressure using a rotary evaporator
and purified as described in Section 2.5.
Post-formulation functionalized nanoparticles (post-formulation Ang–2 NPs) were prepared
as previously described for pre-formulation Ang–2 NPs but using a modified polymer mixture:
PLGA (45%), PLGA-b-PEG (45%), and PLGA-Mal (10%). After purification and resuspension,
the nanoparticles obtained were subsequently modified through covalent binding with Ang–2 in
different PLGA-Mal/Ang–2 molar ratios (3:1, 2:1, and 1:1). For this modification, the corresponding
amount of Ang–2 was dissolved in an aqueous solution, added to the NPs suspension, and reacted
under constant stirring for 15 h [7,29,30]. Finally, Cy5 fluorescently labeled nanoparticles were prepared
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with the following composition: PLGA (42.5%), PLGA-b-PEG (42.5%), PLGA-Cy5 (5%), and PLGA-Mal
(10%), and they were post modified (PLGA-Mal/Ang–2 molar ratio 2:1) in order to carry out in vivo
tests. Nanoparticles without PLGA-Mal were prepared as controls.
2.5. Purification of Nanoparticles
For removal and quantification of free Ang–2 from the post-formulation Ang–2 NPs, the
suspensions obtained were centrifuged for 15 min at a speed of 13,500 rpm using a Spectrafuge™ 24D
microcentrifuge (LabNet, Woodbridge, NJ, USA). The supernatant was removed by decantation, and
the solid was resuspended in Milli-Q water (MerckMillipore, Oregon City, OR, USA). The Ang–2-NP
suspension was then stored in the refrigerator for further analysis.
2.6. Characterization of Nanoparticles
2.6.1. Distribution of Particle Size and Zeta Potential
Particle size, polydispersity index and zeta potential measurements were carried out on a Zetasizer
Nano ZS (Malvern Instrument, Worcestershire, UK) at 25 ◦C, after purification of the NPs. The experiments
were performed in triplicate, and the results are reported as the mean value ± standard deviation.
2.6.2. HPLC Quantification of Ang–2 in Post-Functionalized Nanoparticles
The quantification of Ang–2 conjugated after NP formation (post-formulation) was carried
out indirectly by quantifying the amount of free Ang–2 that remained in the supernatant after NP
purification using high-performance liquid chromatography (HPLC). A 500 µL aliquot of supernatant
was left at RT for 72 h until complete dimerization was achieved, and 50 µL was injected onto a C8
column (Aeris™ WIDEPORE XB-C8, 150 × 4.6 mm, 3.6 µm) using a gradient method where the mobile
phases consisted of 0.1% trifluoroacetic acid (TFA) in water (solution A) and 0.1% TFA in acetonitrile
(ACN) (solution B), where solution B was increased from 10% to 35% over 12 min with a flow of
1.2 mL/min. The amount of Ang–2 in the supernatant was determined with a standard curve designed
by integrating the peak of interest using a UV detector monitoring λ = 215 nm (linear in the range
of 1–50 µg/mL and a correlation coefficient of 0.9991). The difference between the initial amount of
peptide added to the formulation and the amount quantified in the supernatant allowed the calculation
of the percentage of peptide bound to the NPs.
2.7. In Vivo Tests: Brain Uptake of the Nanoparticles
2.7.1. Animal Handling Protocols and Sample Preparation for Systemic Injection of
Post-Functionalized Ang–2 NPs
The post-formulation procedure lead to the production of post-formulation Ang–2 NPs (or as a
control, fresh saline solution lacing NPs), which were suspended in a saline solution and injected i.p.
(100 µL, 1 mg/mL) into C57Bl6 mice (female and male, weight close to 25 g). As control, unmodified
NPs were also administered. After 1 or 4 h, the mice were sacrificed for histological processing: each
mouse was anesthetized with chloral hydrate (400 mg/kg, i.p.) and underwent intracardial perfusion
with an infusion of 50 mL of 0.9% NaCl saline containing heparin sodium (5000 U/L) followed with
4% paraformaldehyde and 0.2% picric acid in phosphate-buffered saline (PBS) (70 mL/7 min) ensued
by extraction of the brain. The brains were post-fixed in the same solution for 12 h, rinsed with
increasing concentrations of sucrose in PBS over 1.5 d, and frozen using dry ice. Coronal sections
(50 µm thick) were cut at a cryotome, washed in cold 1× PBS, and stored at −20 ◦C in a glycerol-PBS
solution until used.
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2.7.2. Immunohistochemistry of Brain Sections
Brain sections were processed for multiple immunofluorescence histochemistry according to
published protocol (ref). Neuronal nuclear antigen (NeuN) (Millipore, USA) from DAKO was used as
the primary antibody, and goat anti-mouse Alexa488 (1:200) or goat anti-rabbit Alexa488 (1:200) were
used as secondary antibodies.
2.7.3. Confocal Analysis
Confocal analysis was performed with a Leica DM IRE 2 (Bannockburn, IL, USA); Leica Confocal
System: scan head multiband 3 channels Leica TCS SP2 with Acousto-Optical Beam Splitter (AOBS)
laser diode blu (405 nm/25 mW), Laser Ar (458 nm/5 mW) (476 nm/5 mW) (488 nm/20 mW)
(496 nm/5 mW) (514 nm/20 mW), Laser HeNe (543 nm/1.2 mW), Laser HeNe (594 nm) (orange),
and Laser HeNe (633 nm/102 mW). In particular, NPs (due to their labeling with Cy5) were clearly
visible by excitation with the 633 nm laser with an emission readout at 650 nm, while staining of NeuN
and other immunohistochemistry tags were detected using 488 and 500 nm excitation and emission
wavelengths, respectively.
3. Results and Discussion
3.1. Quantification of Ang–2 on Modified PLGA by 1H-NMR
The 1H-NMR spectra of PLGA-Mal, Ang–2, and the PLGA modified with Ang–2 (PLGA-Ang–2)
are presented in Figure 3. The intense signals observed at δ = 4.9 and 5.2 ppm in the PLGA-Mal
and PLGA-Ang–2 spectra correspond to the methylene (–CH2) and methine (–CH) groups of the
PLGA. On the other hand, the signals observed in the PLGA-Ang–2 spectrum around δ = 7.0 ppm are
attributed to the aromatic protons present in the amino acids phenylalanine (Phe) and tyrosine (Tyr) of
the peptide, thus confirming the polymer functionalization [28].
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Figure 3. 1H-NMR spectra of PLGA-Mal, Ang–2, and PLGA-Ang2 obtained in deuterated DMSO.
The functionalization degree of PLGA with Ang–2 was calculated from the ratio between the area
of the doublet observed at δ = 6.65, corresponding to aromatic protons of Tyr, and the area of the signal
observed at δ = 1.5, corresponding to the protons of the methyl groups (–CH3) of PLGA. In Equation (1),
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the obtained Ang–2/PLGA relation is shown, where ai corresponds to the integrated area under the
signals of the 1H-NMR spectrum for the respective fractions, mi corresponds to the number of protons
corresponding to each signal, and ni is the number of repetition units of the fraction i. This calculation
indicates that for every PLGA there is 0.51 units of Ang–2 (2:1 PLGA/Ang–2). The modified polymer
was used to prepare the pre-functionalized nanoparticles.
Ang–2
PLGA =
aAng–2 /mAng–2
(aAng–2 /mAng–2 )+(aCH3 /(mCH3 × nCH3 ))
= 4/4
(4/4) + (795.29/(3 × 278)) = 0.51 (1)
3.2. HPLC Quantification of Ang–2 in Post-Functionalized Nanoparticles
Because of the incompatibility of PLGA with HPLC analysis, the amount of Ang–2 bound to the
post-functionalized nanoparticles was determined indirectly from the supernatant obtained during
the purification process using a calibration curve previously constructed from a standard solution of
the peptide. In the chromatograms obtained for the supernatant, two peaks were detected at 2.7 and
3.4 min of retention. By analyzing this solution over time, it is possible to observe the time-dependent
transformation of the first eluted peak into the second, as shown in Figure 4. This conversion of the
product can be explained by disulfide bond formation (dimerization) of the Ang–2 peptide N-terminal
cysteines [31]. Since the formation of the Ang–2 dimer is spontaneous, the complete conversion of the
monomer to the dimer was allowed, and the dimer calibration curve was constructed to carry out the
quantification of the free Ang–2.Pharmaceutics 2019, 11, x FOR PEER REVIEW 7 of 12 
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Figure 4. Chromatographic analysis obtained for the monomer (2.4 min) and the Ang–2 dimer (3.4 min)
after 72 h at room temperature or adding a tris buffer solution at pH 9 only to quickly check the
dimer formation.
Table 1 shows the amount of Ang–2 bound to the nanoparticles for the different ratios of
PLGA-Mal/Ang–2 studied (3:1, 2:1, and 1:1). It was observed that even when PLGA-Mal was not used
in the formulation (no reaction should occur between Ang–2 and PLGA), part of the Ang–2 remained
bound to the nanoparticles. This is due to the nonspecific adsorption of the peptide to the NP surface.
On the other hand, the amount of Ang–2 bound to the NPs increased significantly (P < 0.05) with the
presence of PLGA-Mal in the formulation, which suggests the covalent binding of this peptide with the
polymer. Finally, and as expected, an increase in the amount of Ang–2 per grams of NP was observed
by increasing the amount of initial peptide added to the formulation.
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Table 1. Amount of Ang–2 bound to the nanoparticles determined through HPLC for three different
PLGA-Mal/Ang–2 ratios. The controls correspond to nanoparticles with the same amount of Ang–2 as
the experiment, but without the presence of PLGA-Mal. Values represent mean ± standard deviation
(n = 3 experiments). * and ** show statistically significant differences (P < 0.05) between the label samples.
Initial Amount
PLGA-Mal/Ang–2 µg Ang–2/g NPs
Final Molar Ratio
Ang–2/PLGA-Mal
Control (3:1) 1.65 ± 0.60
3:1 3.06 ± 0.11 0.25 ± 0.01
Control (2:1) 2.59 ± 0.71 *
2:1 4.42 ± 0.74 * 0.37 ± 0.06
Control (1:1) 4.24 ± 0.71 **
1:1 8.78 ± 1.93 ** 0.73 ± 0.23
3.3. Size Distribution and Zeta Potential of Pre- and Post-Functionalized Ang2-NPs
The pre- and post-functionalized Ang2-NPs were characterized through particle size,
polydispersity index, and zeta potential measurements. For comparative purposes, the values of these
variables for NPs without Ang–2 were also determined (Table 2). For all prepared NPs, monomodal
and homogeneous dispersions were obtained (PDI≤ 0.1); however, it was observed that the conjugation
of Ang–2 to the nanoparticles through either strategy led to an increase in particle size compared to
non-functionalized nanoparticles (P < 0.05), which could be related to the presence of peptide onto
NPs. The zeta potential values were lower than −20 mV for all formulations because of the negative
surface charge related with the carboxylic groups of the PLGA.
Table 2. Particle size, polydispersity index, and zeta potential of PLGA-b-PEG nanoparticles pre- and
post-functionalized with Ang–2.
PLGA-b-PEG Formulations Particle Size (nm) PDI Zeta Potential (mV)
Non-functionalized NPs 136.3 ± 6.8 0.06 ± 0.01 −27.4 ± 2.7
Pre-Formulation Ang–2 NPs 166.4 ± 2.4 0.08 ± 0.04 −26.2 ± 0.9
Post-Formulation Ang–2 NPs 177.3 ± 12.7 0.10 ± 0.01 −21.9 ± 3.4
3.4. In Vivo Brain Distribution of Ang–2 NPs
To demonstrate the ability for modified nanoparticles to cross the blood–brain barrier and reach
various brain areas, 100 µL of post-formulation Ang–2 NP suspension (1 mg/mL) was i.p. injected
into C57BL/6 mice. After one or four hours, the mice were sacrificed and the brain was removed
and histologically stained for the presence of cell nuclei (DAPI) and neuronal cells (neuronal nuclear
antigen, NeuN). Representative results were already visible, qualitatively demonstrating penetration
of the Ang–2-NPs across the BBB at 1 h (data not shown), similar to those results obtained at 4 h.
With respect to control samples (unmodified labeled NPs) not showing significant signals related to
NPs (Figure S1), the presence of Ang–2 NPs was uniform throughout the dentate gyrus, cortex, and
hippocampus (Figure 5A, red channel), suggesting a robust, uniform passage of the NPs across the
BBB. The clear accumulation of Ang–2 NPs in brain parenchyma is remarkable in consideration of
the inability of unmodified NPs and modified NPs used as controls (data not shown) to cross BBB
alone (data not shown), which was also broadly assessed from other outputs in literature of NPs of
similar composition and size [30,32]. In analyzing the images, Ang–2-NPs colocalized with the various
cell types present in the brain, evidenced only with DAPI, but were often also in close proximity
to the neuronal cells (Figure 5B, red and yellow arrows respectively). This is interesting because it
could indicate a different mode of cell uptake than what has been seen previously for PLGA NPs
targeted with the simil-opioid peptide ligand g7 [20,27,33] that are broadly up-taken only by neurons.
Moreover, further studies will be required to better elucidate the mechanism of Ang–2 NP entrance
in the brain or in the cells, for instance by blocking endo-transcytosis or the clathrin/caveolin uptake
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process, and therefore to draft a complete hypothesis on BBB-crossing pathways and neuron uptake of
these kinds of NPs. Transcytosis pathways, therefore, could not be evidenced with these remarkable
but preliminary experiments.Phar aceutics 2019, 11, x FOR PEER REVIEW 8 of 12 
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(red channel), and NEUN (green channel). (B) Magnified analysis of the dentate gyrus. (C) Magnified 
analysis of hippocampus. In both images (B,C), colocalization with (red arrows) NEUN negative 
stained cells and colocalization with neurons (yellow arrows) are identified. All images are 
representative of the average analysis, and scale bars in (A–C) are set at 50, 20, and 50 µm, 
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4. Conclusions
In summary, in this work, Ang–2 NPs were prepared by nanoprecipitation using pre- and
post-formulation strategies and using PF127 as a stabilizer. With both methodologies, we obtained NPs
with sizes lower than 200 nm, compatible with systemic administration and to enable possible BBB
crossing. Furthermore, brain accu ulation was, for the first time, confirmed through in vivo analysis,
where we observed the localization of this kind of nanoparticle within the brain cells, highlighting
in particular the neuron accumulation in different brain areas (i.e., cortex and hippocampus). In fact,
even if Ang–2 is not new in the CNS targeting panorama, previous papers dealt with experiments on
different polymers used in production of nanomedicines (as caprolactone [16], a mixture of mesoporous
silica PLGA-based NPs [34]), or different nanocarrier architectures, as in the use of micelles [35].
In any paper, besides some in vivo experiments on BBB crossing, data on cell tropism and clear brain
visualization are not often reported. Therefore, the formulations presented in the current paper could
be used as carriers of different drugs to the CNS, thus increasing the alternatives for the treatment of
brain diseases.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/1/72/s1,
Figure S1: Fluorescent microscopy analysis of non-functionalized NP brain distribution. Staining with DAPI
(blue channel), Cy5- fluorescence (red channel), and NEUN (green channel).
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